Kestrel Therapeutics Receives FDA Fast Track Designation for KST-6051
News related to:Kestrel Therapeutics Inc · 1 min read
WATERTOWN, Mass., Sept. 15, 2026 /CourierPR/ -- Kestrel Therapeutics Inc, a clinical-stage biotechnology company, has received a significant regulatory milestone with the U.S. Food and Drug Administration (FDA) granting Fast Track designation to its lead candidate, KST-6051. This designation is for the treatment of patients with advanced or metastatic solid tumors harboring KRAS mutations.
KST-6051 is described as a potential best-in-class, oral pan-KRAS inhibitor. The designation is based on the strength of the company's preclinical data package, which demonstrated robust on-target pathway modulation, anti-proliferative activity, and efficacy at well-tolerated doses in multiple human KRAS mutant tumor models. The Fast Track designation will facilitate more frequent communication between Kestrel and the FDA as the company advances KST-6051 through its ongoing Phase 1 study, denoted FALCON (NCT07458347).
KST-6051 is currently being evaluated in an ongoing first-in-human (FIH), dose-escalation Phase 1 study. The study, FALCON, is designed to assess the safety, tolerability, and preliminary efficacy of KST-6051 in patients with advanced or metastatic KRAS-mutant solid tumors. The company's clinical development plans ultimately aim to address pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and other KRAS-driven malignancies.
KRAS is estimated to be mutated in approximately 30% of all malignancies, making it a significant target for therapeutic intervention. Kestrel Therapeutics, a privately held clinical-stage biotechnology company, is pioneering small-molecule therapies that directly address oncogenic drivers of cancer, focusing on next-generation inhibitors of mutated KRAS proteins. The company's lead candidate, KST-6051, offers the potential to treat a broad spectrum of KRAS-driven solid tumors, an area of significant unmet patient need.
Kestrel Therapeutics is backed by leading life-science investors, including Pfizer Ventures and Santé Ventures, and has entered into a strategic agreement that grants AbbVie an exclusive option to acquire the company based on defined development milestones. The company is headquartered in Watertown, Massachusetts.